NEUROTECH INTERNATIONAL LIMITED - Announcements

Market Cap $57.99M Add to my watchlist

Healthcare Medical Devices

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Combining science, nature and human compassion, Little Green Pharma (ASX:LGP) are committed to improving the quality of life for sufferers of debilitating chronic conditions. NEWS: Little Green Pharma shares surge as Germany legalises Cannabis.

Announcements

Filter Results

All Price Sensitive Only

NTI	Medicinal Cannabis Presentation		10/03/22	136.55KB	Share
NTI	Proposed issue of securities - NTI		03/03/22	33.94KB	Share
NTI	Appointment of Chief Executive Officer	PRICE SENSITIVE	03/03/22	155.56KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	24/02/22	1.64MB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	959.81KB	Share
NTI	Application for quotation of securities - NTI		24/01/22	24.92KB	Share
NTI	Change of Registry Address		20/12/21	152.9KB	Share
NTI	Change of Director's Interest Notice x 2		13/12/21	309.99KB	Share
NTI	Notification regarding unquoted securities - NTI		13/12/21	23.86KB	Share
NTI	Notification regarding unquoted securities - NTI		13/12/21	23.75KB	Share
NTI	Preclinical Success with Targeted Combination Therapies	PRICE SENSITIVE	01/12/21	321.37KB	Share
NTI	Results of Meeting		18/11/21	156.42KB	Share
NTI	Application for quotation of securities - NTI		16/11/21	24.92KB	Share
NTI	Change of Director's Interest Notice		08/11/21	865.24KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/21	1.56MB	Share
NTI	Investor Presentation		25/10/21	869.26KB	Share
NTI	NTI to Present at the South-West Connect ASX Showcase		25/10/21	106.53KB	Share
NTI	Successful Completion of Preclinical MS Studies		22/10/21	255.73KB	Share
NTI	Annual Report (Typeset)		19/10/21	2.62MB	Share
NTI	Notice of Annual General Meeting/Proxy Form		19/10/21	990.92KB	Share
NTI	Response to ASX Query Letter	PRICE SENSITIVE	14/10/21	295.41KB	Share
NTI	Provisional Patent Lodgements	PRICE SENSITIVE	14/10/21	124.55KB	Share
NTI	Trading Halt	PRICE SENSITIVE	12/10/21	135.33KB	Share
NTI	ASX Listing Rule 3.13.1 Notice Regarding AGM		29/09/21	74.59KB	Share
NTI	NTI164 Clinical Program Update		23/09/21	156.26KB	Share
NTI	IRD Invest Conference - Webinar Presentation		21/09/21	89.28KB	Share
NTI	Ceasing to be a substantial holder		14/09/21	221.04KB	Share
NTI	Appendix 4G and Corporate Governance Statement		30/08/21	451.88KB	Share
NTI	Appendix 4E and Annual Report	PRICE SENSITIVE	30/08/21	1.02MB	Share
NTI	Investor Webinar Presentation		05/08/21	78.67KB	Share
NTI	Investor Presentation		05/08/21	1.35MB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	30/07/21	365.86KB	Share
NTI	Phase I/II Clinical Trial Update		21/07/21	352.91KB	Share
NTI	Change of Director's Interest Notice		20/07/21	152.81KB	Share
NTI	Change of Director's Interest Notice		15/07/21	175.93KB	Share
NTI	Further Success with Preclinical Testing Program - MS Models		07/07/21	147.75KB	Share
NTI	Appendix 3G		01/07/21	244.29KB	Share
NTI	Update - Proposed issue of securities - NTI		29/06/21	28.22KB	Share
NTI	NTI to Present at the Gold Coast Investment Showcase		23/06/21	64.12KB	Share
NTI	Change of Director's Interest Notice		23/06/21	158.13KB	Share
NTI	Investor Presentation		16/06/21	1.23MB	Share
NTI	NTI Strains Demonstrate Potential Benefits for MS Management		25/05/21	124.93KB	Share
NTI	Proposed issue of Securities - NTI		20/05/21	25.09KB	Share
NTI	Initial Director's Interest Notice		20/05/21	136.87KB	Share
NTI	Appointment of Allan Cripps as Non-Executive Director		20/05/21	75.35KB	Share
NTI	Appendix 2A		19/05/21	300.42KB	Share
NTI	Appendix 2A		12/05/21	215.92KB	Share
NTI	Update - Proposed issue of Securities - NTI		12/05/21	27.97KB	Share
NTI	Update - Proposed issue of Securities - NTI		12/05/21	27.89KB	Share
NTI	Results of Meeting		07/05/21	124.53KB	Share
NTI	Neurotech initiates Phase I/II Open Label Study into Autism		05/05/21	96KB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	03/05/21	295.97KB	Share
NTI	Update - Proposed issue of Securities - NTI		23/04/21	27.24KB	Share
NTI	Proposed issue of Securities - NTI		19/04/21	27.49KB	Share
NTI	Disclosure Document		19/04/21	452.42KB	Share
NTI	Appendix 2A		16/04/21	218.4KB	Share
NTI	Change of Director's Interest Notice		15/04/21	137.97KB	Share
NTI	Initial Director's Interest Notice		12/04/21	132.62KB	Share
NTI	Notice of General Meeting/Proxy Form		07/04/21	1007.46KB	Share
NTI	Proposed issue of Securities - NTI		06/04/21	27.22KB	Share
NTI	Appointment of Krista Bates as Non-Executive Director		06/04/21	75.25KB	Share
NTI	Appendix 2A		01/04/21	300KB	Share
NTI	Human Clinical Trial Update		31/03/21	98.28KB	Share
NTI	Appendix 2A		26/03/21	300.04KB	Share
NTI	Appendix 2A		19/03/21	300.17KB	Share
NTI	Appendix 2A		15/03/21	223.6KB	Share
NTI	Proposed issue of Securities - NTI		15/03/21	27.52KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	15/03/21	401.87KB	Share
NTI	Proposed issue of Securities - NTI		09/03/21	26.57KB	Share
NTI	Strategic Cultivation Partnership with CannaPacific		09/03/21	111.61KB	Share
NTI	Notice of Expiry of Listed Options		04/03/21	119.06KB	Share
NTI	Appendix 2A		04/03/21	216.27KB	Share
NTI	Proposed issue of Securities - NTI		02/03/21	24.7KB	Share
NTI	Proposed issue of Securities - NTI		02/03/21	24.62KB	Share
NTI	Proposed issue of Securities - NTI		02/03/21	26.78KB	Share
NTI	Proposed issue of Securities - NTI		02/03/21	26.83KB	Share
NTI	Proposed issue of Securities - NTI		02/03/21	25.48KB	Share
NTI	Proposed issue of Securities - NTI		02/03/21	25.23KB	Share
NTI	Neurotech Expands License with Dolce Cann Global	PRICE SENSITIVE	02/03/21	82.52KB	Share
NTI	Neurotech Secures $3.56m in Funding	PRICE SENSITIVE	02/03/21	165.7KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	26/02/21	661.89KB	Share
NTI	Trading Halt	PRICE SENSITIVE	26/02/21	173.33KB	Share
NTI	Phase One and Two Clinical Program Update		15/02/21	122.56KB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	29/01/21	369.81KB	Share
NTI	Q&A with NTI Company Chairman, Brian Leedman		20/01/21	111.38KB	Share
NTI	Change of Director's Interest Notice		22/12/20	128.77KB	Share
NTI	Appendix 2A		22/12/20	304.01KB	Share
NTI	Results of Meeting		22/12/20	126.24KB	Share
NTI	Successful Completion of In Vitro Studies	PRICE SENSITIVE	21/12/20	384.21KB	Share
NTI	Change of Director's Interest Notice x 3		17/12/20	459.43KB	Share
NTI	Update - Proposed issue of Securities - NTI		17/12/20	32.41KB	Share
NTI	Update - Proposed issue of Securities - NTI		17/12/20	28.02KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	16/12/20	454.41KB	Share
NTI	Appendix 2A		11/12/20	218.84KB	Share
NTI	Results of Meeting		30/11/20	115.72KB	Share
NTI	Reinstatement to Official Quotation	PRICE SENSITIVE	30/11/20	402.35KB	Share
NTI	Further Success with Preliminary In-vitro Studies	PRICE SENSITIVE	30/11/20	128.54KB	Share
NTI	Voluntary Suspension	PRICE SENSITIVE	27/11/20	159.73KB	Share
NTI	Trading Halt	PRICE SENSITIVE	24/11/20	480.17KB	Share
NTI	Notice of General Meeting/Proxy Form		23/11/20	898.36KB	Share

NTI Medicinal Cannabis Presentation
10/03/22		136.55KB	Share
NTI Proposed issue of securities - NTI
03/03/22		33.94KB	Share
NTI Appointment of Chief Executive Officer
03/03/22	PRICE SENSITIVE	155.56KB	Share
NTI Appendix 4D and Half Year Accounts
24/02/22	PRICE SENSITIVE	1.64MB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	959.81KB	Share
NTI Application for quotation of securities - NTI
24/01/22		24.92KB	Share
NTI Change of Registry Address
20/12/21		152.9KB	Share
NTI Change of Director's Interest Notice x 2
13/12/21		309.99KB	Share
NTI Notification regarding unquoted securities - NTI
13/12/21		23.86KB	Share
NTI Notification regarding unquoted securities - NTI
13/12/21		23.75KB	Share
NTI Preclinical Success with Targeted Combination Therapies
01/12/21	PRICE SENSITIVE	321.37KB	Share
NTI Results of Meeting
18/11/21		156.42KB	Share
NTI Application for quotation of securities - NTI
16/11/21		24.92KB	Share
NTI Change of Director's Interest Notice
08/11/21		865.24KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/10/21	PRICE SENSITIVE	1.56MB	Share
NTI Investor Presentation
25/10/21		869.26KB	Share
NTI NTI to Present at the South-West Connect ASX Showcase
25/10/21		106.53KB	Share
NTI Successful Completion of Preclinical MS Studies
22/10/21		255.73KB	Share
NTI Annual Report (Typeset)
19/10/21		2.62MB	Share
NTI Notice of Annual General Meeting/Proxy Form
19/10/21		990.92KB	Share
NTI Response to ASX Query Letter
14/10/21	PRICE SENSITIVE	295.41KB	Share
NTI Provisional Patent Lodgements
14/10/21	PRICE SENSITIVE	124.55KB	Share
NTI Trading Halt
12/10/21	PRICE SENSITIVE	135.33KB	Share
NTI ASX Listing Rule 3.13.1 Notice Regarding AGM
29/09/21		74.59KB	Share
NTI NTI164 Clinical Program Update
23/09/21		156.26KB	Share
NTI IRD Invest Conference - Webinar Presentation
21/09/21		89.28KB	Share
NTI Ceasing to be a substantial holder
14/09/21		221.04KB	Share
NTI Appendix 4G and Corporate Governance Statement
30/08/21		451.88KB	Share
NTI Appendix 4E and Annual Report
30/08/21	PRICE SENSITIVE	1.02MB	Share
NTI Investor Webinar Presentation
05/08/21		78.67KB	Share
NTI Investor Presentation
05/08/21		1.35MB	Share
NTI Quarterly Report and Appendix 4C
30/07/21	PRICE SENSITIVE	365.86KB	Share
NTI Phase I/II Clinical Trial Update
21/07/21		352.91KB	Share
NTI Change of Director's Interest Notice
20/07/21		152.81KB	Share
NTI Change of Director's Interest Notice
15/07/21		175.93KB	Share
NTI Further Success with Preclinical Testing Program - MS Models
07/07/21		147.75KB	Share
NTI Appendix 3G
01/07/21		244.29KB	Share
NTI Update - Proposed issue of securities - NTI
29/06/21		28.22KB	Share
NTI NTI to Present at the Gold Coast Investment Showcase
23/06/21		64.12KB	Share
NTI Change of Director's Interest Notice
23/06/21		158.13KB	Share
NTI Investor Presentation
16/06/21		1.23MB	Share
NTI NTI Strains Demonstrate Potential Benefits for MS Management
25/05/21		124.93KB	Share
NTI Proposed issue of Securities - NTI
20/05/21		25.09KB	Share
NTI Initial Director's Interest Notice
20/05/21		136.87KB	Share
NTI Appointment of Allan Cripps as Non-Executive Director
20/05/21		75.35KB	Share
NTI Appendix 2A
19/05/21		300.42KB	Share
NTI Appendix 2A
12/05/21		215.92KB	Share
NTI Update - Proposed issue of Securities - NTI
12/05/21		27.97KB	Share
NTI Update - Proposed issue of Securities - NTI
12/05/21		27.89KB	Share
NTI Results of Meeting
07/05/21		124.53KB	Share
NTI Neurotech initiates Phase I/II Open Label Study into Autism
05/05/21		96KB	Share
NTI Quarterly Report and Appendix 4C
03/05/21	PRICE SENSITIVE	295.97KB	Share
NTI Update - Proposed issue of Securities - NTI
23/04/21		27.24KB	Share
NTI Proposed issue of Securities - NTI
19/04/21		27.49KB	Share
NTI Disclosure Document
19/04/21		452.42KB	Share
NTI Appendix 2A
16/04/21		218.4KB	Share
NTI Change of Director's Interest Notice
15/04/21		137.97KB	Share
NTI Initial Director's Interest Notice
12/04/21		132.62KB	Share
NTI Notice of General Meeting/Proxy Form
07/04/21		1007.46KB	Share
NTI Proposed issue of Securities - NTI
06/04/21		27.22KB	Share
NTI Appointment of Krista Bates as Non-Executive Director
06/04/21		75.25KB	Share
NTI Appendix 2A
01/04/21		300KB	Share
NTI Human Clinical Trial Update
31/03/21		98.28KB	Share
NTI Appendix 2A
26/03/21		300.04KB	Share
NTI Appendix 2A
19/03/21		300.17KB	Share
NTI Appendix 2A
15/03/21		223.6KB	Share
NTI Proposed issue of Securities - NTI
15/03/21		27.52KB	Share
NTI Disclosure Document
15/03/21	PRICE SENSITIVE	401.87KB	Share
NTI Proposed issue of Securities - NTI
09/03/21		26.57KB	Share
NTI Strategic Cultivation Partnership with CannaPacific
09/03/21		111.61KB	Share
NTI Notice of Expiry of Listed Options
04/03/21		119.06KB	Share
NTI Appendix 2A
04/03/21		216.27KB	Share
NTI Proposed issue of Securities - NTI
02/03/21		24.7KB	Share
NTI Proposed issue of Securities - NTI
02/03/21		24.62KB	Share
NTI Proposed issue of Securities - NTI
02/03/21		26.78KB	Share
NTI Proposed issue of Securities - NTI
02/03/21		26.83KB	Share
NTI Proposed issue of Securities - NTI
02/03/21		25.48KB	Share
NTI Proposed issue of Securities - NTI
02/03/21		25.23KB	Share
NTI Neurotech Expands License with Dolce Cann Global
02/03/21	PRICE SENSITIVE	82.52KB	Share
NTI Neurotech Secures $3.56m in Funding
02/03/21	PRICE SENSITIVE	165.7KB	Share
NTI Appendix 4D and Half Year Accounts
26/02/21	PRICE SENSITIVE	661.89KB	Share
NTI Trading Halt
26/02/21	PRICE SENSITIVE	173.33KB	Share
NTI Phase One and Two Clinical Program Update
15/02/21		122.56KB	Share
NTI Quarterly Report and Appendix 4C
29/01/21	PRICE SENSITIVE	369.81KB	Share
NTI Q&A with NTI Company Chairman, Brian Leedman
20/01/21		111.38KB	Share
NTI Change of Director's Interest Notice
22/12/20		128.77KB	Share
NTI Appendix 2A
22/12/20		304.01KB	Share
NTI Results of Meeting
22/12/20		126.24KB	Share
NTI Successful Completion of In Vitro Studies
21/12/20	PRICE SENSITIVE	384.21KB	Share
NTI Change of Director's Interest Notice x 3
17/12/20		459.43KB	Share
NTI Update - Proposed issue of Securities - NTI
17/12/20		32.41KB	Share
NTI Update - Proposed issue of Securities - NTI
17/12/20		28.02KB	Share
NTI Disclosure Document
16/12/20	PRICE SENSITIVE	454.41KB	Share
NTI Appendix 2A
11/12/20		218.84KB	Share
NTI Results of Meeting
30/11/20		115.72KB	Share
NTI Reinstatement to Official Quotation
30/11/20	PRICE SENSITIVE	402.35KB	Share
NTI Further Success with Preliminary In-vitro Studies
30/11/20	PRICE SENSITIVE	128.54KB	Share
NTI Voluntary Suspension
27/11/20	PRICE SENSITIVE	159.73KB	Share
NTI Trading Halt
24/11/20	PRICE SENSITIVE	480.17KB	Share
NTI Notice of General Meeting/Proxy Form
23/11/20		898.36KB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 5.7¢		Change -0.005(8.06%)		Mkt cap ! $57.99M

Open	High	Low	Value	Volume
6.5¢	6.5¢	5.5¢	$194.8K	3.233M

Buyers (Bids)

No.	Vol.	Price($)
2	22241	5.8¢

Sellers (Offers)

Price($)	Vol.	No.
6.1¢	152989	2

View Market Depth

No.	Vol.	Price($)
2	22241	0.058
4	170363	0.057
1	71719	0.055
1	16745	0.054
1	47909	0.051

Price($)	Vol.	No.
0.061	152989	2
0.063	250000	1
0.064	207847	1
0.065	9876	1
0.069	174000	1

Last trade - 15.59pm 05/06/2024 (20 minute delay)


Last 5.8¢		Change -0.005 ( 7.94 %)
Open	High	Low	Volume
6.4¢	6.4¢	5.7¢	600782
Last updated 15.59pm 05/06/2024 ?

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories